Moderna
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2010-01-01
- Employees
- 5.6K
- Market Cap
- $30.3B
- Website
- http://www.modernatx.com
- Introduction
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ≥12 Years of Age to Prevent COVID-19
- Conditions
- COVID-19
- Interventions
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 14246
- Registration Number
- NCT05815498
- Locations
- 🇺🇸
Optimal Research, Huntsville, Alabama, United States
🇺🇸Accel Research Sites- Achieve Clinical Research, Vestavia Hills, Alabama, United States
🇺🇸Chandler Clinical Trials, Chandler, Arizona, United States
A Retrospective Study to Characterize Participants With Propionic Acidemia and Methylmalonic Acidemia
- Conditions
- Methylmalonic AcidemiaPropionic Acidemia
- First Posted Date
- 2023-03-15
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT05769621
- Locations
- 🇺🇸
University of Stanford Medical Center, Stanford, California, United States
🇺🇸Johns Hopkins University, Lutherville, Maryland, United States
🇺🇸University of Michigan Hospital, Ann Arbor, Michigan, United States
An Observational Study of Moderna COVID-19 Bivalent Vaccines (Original and Omicron BA.4/BA.5) and 2023 Updated mRNA COVID-19 Vaccines (XBB.1.5)
- Conditions
- COVID-19
- Interventions
- Biological: Pfizer COVID-19 VaccineBiological: Moderna COVID-19 VaccineBiological: Pfizer 2023 Updated COVID-19 vaccine (XBB.1.5)Biological: Moderna 2023 Updated COVID-19 vaccine (XBB.1.5)Biological: Moderna mRNA1273.222 Booster
- First Posted Date
- 2023-03-13
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 1713
- Registration Number
- NCT05765578
- Locations
- 🇺🇸
Science37, Culver City, California, United States
A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months
- Conditions
- Respiratory Syncytial VirusHuman Metapneumovirus
- Interventions
- First Posted Date
- 2023-02-24
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 310
- Registration Number
- NCT05743881
- Locations
- 🇺🇸
Matrix Clinical Research, Los Angeles, California, United States
🇺🇸Los Angeles Children's Hospital, Los Angeles, California, United States
🇺🇸Velocity Clinical Research, Denver, Englewood, Colorado, United States
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of Age
- Conditions
- Herpes Zoster
- Interventions
- First Posted Date
- 2023-01-27
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 659
- Registration Number
- NCT05701800
- Locations
- 🇺🇸
Velocity Clinical Research - Westlake, Los Angeles, California, United States
🇺🇸Tekton Research, Inc - Longmont Center, Longmont, Colorado, United States
🇺🇸Meridien Research, Lakeland, Florida, United States
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants.
- Conditions
- Cytomegalovirus Infection
- Interventions
- Biological: Placebo
- First Posted Date
- 2023-01-13
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 224
- Registration Number
- NCT05683457
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
A Study to Evaluate the Safety of mRNA-0184 in Participants With Heart Failure
- First Posted Date
- 2022-12-21
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT05659264
- Locations
- 🇺🇸
Cardiology PC, Birmingham, Alabama, United States
🇺🇸University of Alabama at Birmingham: The Kirklin Clinic, Birmingham, Alabama, United States
🇺🇸University of Florida, Gainesville, Florida, United States
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults
- Conditions
- Influenza
- Interventions
- Biological: Egg-based Quadrivalent Influenza VaccineBiological: Adjuvanted Quadrivalent Influenza VaccineBiological: Inactivated Influenza Vaccine
- First Posted Date
- 2022-11-07
- Last Posted Date
- 2025-03-11
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 325
- Registration Number
- NCT05606965
- Locations
- 🇺🇸
Washington University in St. Louis, Saint Louis, Missouri, United States
A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RSV]) or mRNA-1230 (Influenza, RSV, and Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) Vaccine in Adults 50 to 75 Years Old
- Conditions
- SARS-CoV-2RSVInfluenza
- Interventions
- Biological: mRNA-1010Biological: mRNA-1345Biological: mRNA-1273.214Biological: mRNA-1230Biological: mRNA-1045
- First Posted Date
- 2022-10-19
- Last Posted Date
- 2024-03-08
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 392
- Registration Number
- NCT05585632
- Locations
- 🇺🇸
Accel Research Sites, Saint Petersburg, Florida, United States
🇺🇸Research Centers of America (cenexel), Hollywood, Florida, United States
🇺🇸Atlanta Center for Medical Research - Family Medicine, Atlanta, Georgia, United States
Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants
- First Posted Date
- 2022-10-18
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 68
- Registration Number
- NCT05584202
- Locations
- 🇺🇸
Trinity Clinical Research, LLC - Bessemer, Bessemer, Alabama, United States
🇺🇸UAB Pediatrics, Birmingham, Alabama, United States
🇺🇸Eclipse Clinical Research, Tucson, Arizona, United States